Interleukin-6, a major cytokine in the central nervous system

International Journal of Biological Sciences

Volumn 8, Issue 9, 2012, Pages 1254-1266

  Erta, María ^a   Quintana, Albert ^b   Hidalgo, Juan ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Alzheimer's disease; Gliogenesis; Multiple sclerosis; Neurogenesis; Neuroinflammation; Neuropoietin; Stroke; Trauma

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR;

ANIMAL; BIOLOGICAL MODEL; BRAIN INJURY; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; GENETICS; HUMAN; METABOLISM; MOUSE; NERVOUS SYSTEM DEVELOPMENT; PATHOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; BRAIN INJURIES; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; INTERLEUKIN-6; MICE; MODELS, BIOLOGICAL; NEUROGENESIS; RECEPTORS, INTERLEUKIN-6;

ANIMALIA;

EID: 84869857934     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.4679     Document Type: Review

References (242)

1. Hirano T, Taga T, Nakano N, Yasukawa K, Kashiwamura S, Shimizu K, et al. Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). Proc Natl Acad Sci U S A. 1985; 82: 5490-5494.
2. Yasukawa K, Hirano T, Watanabe Y, Muratani K, Matsuda T, Nakai S, et al. Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene. EMBO J. 1987; 6: 2939-2945.
3. Yamasaki K, Taga T, Hirata Y, Yawata H, Kawanishi Y, Seed B, et al. Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science. 1988; 241: 825-828.
4. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cyto-kines and gp130. Blood. 1995; 86: 1243-1254.
5. Wang X, Lupardus P, Laporte SL, Garcia KC. Structural biology of shared cytokine receptors. Annu Rev Immunol. 2009; 27: 29-60.
6. Bazan JF. Haemopoietic receptors and helical cytokines. Immunol Today. 1990; 11: 350-354.
7. Bazan JF. Neuropoietic cytokines in the hematopoietic fold. Neuron. 1991; 7: 197-208.
8. Taga T, Kishimoto T. Cytokine receptors and signal transduction. FASEB J. 1992; 6: 3387-3396.
9. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003; 374: 1-20.
10. Bauer S, Kerr BJ, Patterson PH. The neuropoietic cytokine family in development, plasticity, disease and injury. Nat Rev Neurosci. 2007; 8: 221-232.
11. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science. 2003; 300: 2101-2104.
12. Saito M, Yoshida K, Hibi M, Taga T, Kishimoto T. Molecular cloning of a murine IL-6 receptor-associated signal transducer, gp130, and its regulated expression in vivo. J Immunol. 1992; 148: 4066-4071.
13. Rose-John S, Waetzig GH, Scheller J, Grötzinger J, Seegert D. The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets. 2007; 11: 613-624.
14. Narazaki M, Yasukawa K, Saito T, Ohsugi Y, Fukui H, Koishihara Y, et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood. 1993; 82: 1120-1126.
15. Satoh T, Nakamura S, Taga T, Matsuda T, Hirano T, Kishimoto T, et al. Induction of neuronal differentiation in PC12 cells by B-cell stimulatory factor 2/interleukin 6. Mol Cell Biol. 1988; 8: 3546-3549.
16. Nakafuku M, Satoh T, Kaziro Y. Differentiation factors, including nerve growth factor, fibroblast growth factor, and interleukin-6, induce an accumulation of an active Ras.GTP complex in rat pheochromocytoma PC12 cells. J Biol Chem. 1992; 267: 19448-19454.
17. Cornfield LJ, Sills MA. High affinity interleukin-6 binding sites in bovine hypothalamus. Eur J Pharmacol. 1991; 202: 113-115.
18. Schöbitz B, Voorhuis DA, De Kloet ER. Localization of interleukin 6 mRNA and interleukin 6 receptor mRNA in rat brain. Neurosci Lett. 1992; 136: 189-192.
19. Yan HQ, Banos MA, Herregodts P, Hooghe R, Hooghe-Peters EL. Expression of interleukin (IL)-1 beta, IL-6 and their respective receptors in the normal rat brain and after injury. Eur J Immunol. 1992; 22: 2963-2971.
20. Schöbitz B, de Kloet ER, Sutanto W, Holsboer F. Cellular localization of interleukin 6 mRNA and interleukin 6 receptor mRNA in rat brain. Eur J Neurosci. 1993; 5: 1426-1435.
21. Gadient RA, Otten U. Differential expression of interleukin-6 (IL-6) and interleukin-6 receptor (IL-6R) mRNAs in rat hypothalamus. Neurosci Lett. 1993; 153: 13-16.
22. Gadient RA, Otten U. Identification of interleukin-6 (IL-6)-expressing neurons in the cerebellum and hippocampus of normal adult rats. Neu-rosci Lett. 1994; 182: 243-246.
23. Gadient RA, Otten U. Expression of interleukin-6 (IL-6) and interleukin-6 receptor (IL-6R) mRNAs in rat brain during postnatal development. Brain Res. 1994; 637: 10-14.
24. Vallières L, Rivest S. Regulation of the genes encoding interleukin-6, its receptor, and gp130 in the rat brain in response to the immune activator lipopolysaccharide and the proinflammatory cytokine interleukin-1beta. J Neurochem. 1997; 69: 1668-1683.
25. Sawada M, Itoh Y, Suzumura A, Marunouchi T. Expression of cytokine receptors in cultured neuronal and glial cells. Neurosci Lett. 1993; 160: 131-134.
26. Cannella B, Raine CS. Multiple sclerosis: cytokine receptors on oli-godendrocytes predict innate regulation. Ann Neurol. 2004; 55: 46-57.
27. Gadient RA, Otten U. Postnatal expression of interleukin-6 (IL-6) and IL-6 receptor (IL-6R) mRNAs in rat sympathetic and sensory ganglia. Brain Res. 1996; 724: 41-46.
28. Gadient RA, Lachmund A, Unsicker K, Otten U. Expression of interleu-kin-6 (IL-6) and IL-6 receptor mRNAs in rat adrenal medulla. Neurosci Lett. 1995; 194: 17-20.
29. März P, Gadient RA, Otten U. Expression of interleukin-6 receptor (IL-6R) and gp130 mRNA in PC12 cells and sympathetic neurons: modulation by tumor necrosis factor alpha (TNF-alpha). Brain Res. 1996; 706: 71-79.
30. März P, Cheng JG, Gadient RA, Patterson PH, Stoyan T, Otten U, et al. Sympathetic neurons can produce and respond to interleukin 6. Proc Natl Acad Sci U S A. 1998; 95: 3251-3256.
31. Jirik FR, Podor TJ, Hirano T, Kishimoto T, Loskutoff DJ, Carson DA, et al. Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells. J Immunol. 1989; 142: 144-147.
32. Modur V, Li Y, Zimmerman GA, Prescott SM, McIntyre TM. Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha. J Clin Invest. 1997; 100: 2752-2756.
33. Reyes TM, Fabry Z, Coe CL. Brain endothelial cell production of a neu-roprotective cytokine, interleukin-6, in response to noxious stimuli. Brain Res. 1999; 851: 215-220.
34. Frei K, Malipiero UV, Leist TP, Zinkernagel RM, Schwab ME, Fontana A. On the cellular surface and function of interleukin-6 produced in the central nervous system in viral diseases. Eur J Immunol. 1989; 19: 689-694.
35. Righi M, Mori L, De Libero G, Sironi M, Biondi A, Mantovani A, et al. Monokine production by microglial cell clones. Eur J Immunol. 1989; 19: 1443-1448.
36. Ringheim GE, Burgher KL, Heroux JA. Interleukin-6 mRNA expression by cortical neurons in culture: evidence for neuronal sources of inter-leukin-6 production in the brain. J Neuroimmunol. 1995; 63: 113-123.
37. Benveniste EN, Sparacio SM, Norris JG, Grenett HE, Fuller GM. Induction and regulation of interleukin-6 gene expression in rat astrocytes. J Neuroimmunol. 1990; 30: 201-212.
38. Aloisi F, Carè A, Borsellino G, Gallo P, Rosa S, Bassani A, et al. Production of hemolymphopoietic cytokines (IL-6, IL-8, colony-stimulating factors) by normal human astrocytes in response to IL-1 beta and tumor necrosis factor-alpha. J Immunol. 1992; 149: 2358-2366.
39. Sparacio SM, Zhang Y, Vilcek J, Benveniste EN. Cytokine regulation of interleukin-6 gene expression in astrocytes involves activation of an NF-kappa B-like nuclear protein. J Neuroimmunol. 1992; 39: 231-242.
40. Norris JG, Tang LP, Sparacio SM, Benveniste EN. Signal transduction pathways mediating astrocyte IL-6 induction by IL-1 beta and tumor necrosis factor-alpha. J Immunol. 1994; 152: 841-850.
41. Cadman ED, Witte DG, Lee CM. Regulation of the release of interleu-kin-6 from human astrocytoma cells. J Neurochem. 1994; 63: 980-987.
42. Cadman ED, Naugles DD, Lee CM. cAMP is not involved in interleu-kin-1-induced interleukin-6 release from human astrocytoma cells. Neurosci Lett. 1994; 178: 251-254.
43. Sallmann S, Jüttler E, Prinz S, Petersen N, Knopf U, Weiser T, et al. Induction of interleukin-6 by depolarization of neurons. J Neurosci. 2000; 20: 8637-8642.
44. Ali C, Nicole O, Docagne F, Lesne S, MacKenzie ET, Nouvelot A, et al. Ischemia-induced interleukin-6 as a potential endogenous neuroprotec-tive cytokine against NMDA receptor-mediated excitotoxicity in the brain. J Cereb Blood Flow Metab 2000. 2000; 20: 956-966.
45. Sawada M, Suzumura A, Marunouchi T. TNF alpha induces IL-6 production by astrocytes but not by microglia. Brain Res. 1992; 583: 296-299.
46. Lee SC, Liu W, Dickson DW, Brosnan CF, Berman JW. Cytokine production by human fetal microglia and astrocytes. Differential induction by lipopolysaccharide and IL-1 beta. J Immunol. 1993; 150: 2659-2667.
47. Woodroofe MN, Sarna GS, Wadhwa M, Hayes GM, Loughlin AJ, Tinker A, et al. Detection of interleukin-1 and interleukin-6 in adult rat brain, following mechanical injury, by in vivo microdialysis: evidence of a role for microglia in cytokine production. J Neuroimmunol 1991; 33: 227-236.
48. Sébire G, Emilie D, Wallon C, Héry C, Devergne O, Delfraissy JF, et al. In vitro production of IL-6, IL-1 beta, and tumor necrosis factor-alpha by human embryonic microglial and neural cells. J Immunol. 1993; 150: 1517-1523.
49. Suzumura A, Sawada M, Marunouchi T. Selective induction of interleu-kin-6 in mouse microglia by granulocyte-macrophage colony-stimulating factor. Brain Res. 1996; 713: 192-198.
50. Hashioka S, Klegeris A, Monji A, Kato T, Sawada M, McGeer PL, et al. Antidepressants inhibit interferon-gamma-induced microglial production of IL-6 and nitric oxide. Exp Neurol. 2007; 206: 33-42.
51. Hariri RJ, Chang VA, Barie PS, Wang RS, Sharif SF, Ghajar JB. Traumatic injury induces interleukin-6 production by human astrocytes. Brain Res. 1994; 636: 139-142.
52. Van Wagoner NJ, Oh JW, Repovic P, Benveniste EN. Interleukin-6 (IL-6) production by astrocytes: autocrine regulation by IL-6 and the soluble IL-6 receptor. J Neurosci. 1999; 19: 5236-5244.
53. Ma X, Reynolds SL, Baker BJ, Li X, Benveniste EN, Qin H. IL-17 enhancement of the IL-6 signaling cascade in astrocytes. J Immunol. 2010; 184: 4898-4906.
54. Norris JG, Benveniste EN. Interleukin-6 production by astrocytes: induction by the neurotransmitter norepinephrine. J Neuroimmunol. 1993; 45: 137-145.
55. Maimone D, Cioni C, Rosa S, Macchia G, Aloisi F, Annunziata P. Nore-pinephrine and vasoactive intestinal peptide induce IL-6 secretion by astrocytes: synergism with IL-1 beta and TNF alpha. J Neuroimmunol. 1993; 47: 73-81.
56. Gottschall PE, Tatsuno I, Arimura A. Regulation of interleukin-6 (IL-6) secretion in primary cultured rat astrocytes: synergism of interleukin-1 (IL-1) and pituitary adenylate cyclase activating polypeptide (PACAP). Brain Res. 1994; 637: 197-203.
57. Schettini G, Grimaldi M, Navarra P, Pozzoli G, Reichlin S, Preziosi P. Regulation of interleukin 6 production by cAMP-protein kinase-A pathway in rat cortical astrocytes. Pharmacol Res. 1994; 30: 13-24.
58. Grimaldi M, Pozzoli G, Navarra P, Preziosi P, Schettini G. Vasoactive intestinal peptide and forskolin stimulate interleukin 6 production by rat cortical astrocytes in culture via a cyclic AMP-dependent, prostaglan-din-independent mechanism. J Neurochem. 1994; 63: 344-350.
59. Fiebich BL, Hüll M, Lieb K, Gyufko K, Berger M, Bauer J. Prostaglandin E2 induces interleukin-6 synthesis in human astrocytoma cells. J Neu-rochem. 1997; 68: 704-709.
60. Fiebich BL, Hüll M, Lieb K, Schumann G, Berger M, Bauer J. Potential link between interleukin-6 and arachidonic acid metabolism in Alzheimer's disease. J Neural Transm Suppl. 1998; 54: 268-278.
61. Fiebich BL, Lieb K, Berger M, Bauer J. Stimulation of the sphingomyelin pathway induces interleukin-6 gene expression in human astrocytoma cells. J Neuroimmunol. 1995; 63: 207-211.
62. Gitter BD, Regoli D, Howbert JJ, Glasebrook AL, Waters DC. Interleu-kin-6 secretion from human astrocytoma cells induced by substance P. J Neuroimmunol. 1994; 51: 101-108.
63. Lieb K, Schaller H, Bauer J, Berger M, Schulze-Osthoff K, Fiebich BL. Substance P and histamine induce interleukin-6 expression in human astrocytoma cells by a mechanism involving protein kinase C and nuclear factor-IL-6. J Neurochem. 1998; 70: 1577-8315.
64. Schwaninger M, Sallmann S, Petersen N, Schneider A, Prinz S, Libermann TA, et al. Bradykinin induces interleukin-6 expression in as-trocytes through activation of nuclear factor-kappaB. J Neurochem. 1999; 73: 1461-1466.
65. Fiebich BL, Biber K, Gyufko K, Berger M, Bauer J, van Calker D. Adeno-sine A2b receptors mediate an increase in interleukin (IL)-6 mRNA and IL-6 protein synthesis in human astroglioma cells. J Neurochem. 1996; 66: 1426-1431.
66. Lieb K, Biersack L, Waschbisch A, Orlikowski S, Akundi RS, Candelar-io-Jalil E, et al. Serotonin via 5-HT7 receptors activates p38 mito-gen-activated protein kinase and protein kinase C epsilon resulting in interleukin-6 synthesis in human U373 MG astrocytoma cells. J Neuro-chem. 2005; 93: 549-559.
67. Schwaninger M, Petersen N, Prinz S, Sallmann S, Neher M, Spranger M. Adenosine-induced expression of interleukin-6 in astrocytes through protein kinase A and NF-IL-6. Glia. 2000; 31: 51-58.
68. Suzumura A, Sawada M, Yamamoto H, Marunouchi T. Transforming growth factor-beta suppresses activation and proliferation of microglia in vitro. J Immunol. 1993; 151: 2150-2158.
69. Benveniste EN, Kwon J, Chung WJ, Sampson J, Pandya K, Tang LP. Differential modulation of astrocyte cytokine gene expression by TGF-beta. J Immunol. 1994; 153: 5210-5221.
70. Oh YJ, O'Malley KL. IL-6 increases choline acetyltransferase but not neuropeptide transcripts in sympathetic neurons. Neuroreport. 1994; 5: 937-940.
71. Fann MJ, Patterson PH. Neuropoietic cytokines and activin A differentially regulate the phenotype of cultured sympathetic neurons. Proc Natl Acad Sci U S A. 1994; 91: 43-47.
72. Zhong J, Dietzel ID, Wahle P, Kopf M, Heumann R. Sensory impairments and delayed regeneration of sensory axons in interleu-kin-6-deficient mice. J Neurosci. 1999; 19: 4305-4313.
73. Cafferty WB, Gardiner NJ, Das P, Qiu J, McMahon SB, Thompson SW. Conditioning injury-induced spinal axon regeneration fails in interleu-kin-6 knock-out mice. J Neurosci. 2004; 24: 4432-4443.
74. Ramer MS, Murphy PG, Richardson PM, Bisby MA. Spinal nerve lesion-induced mechanoallodynia and adrenergic sprouting in sensory ganglia are attenuated in interleukin-6 knockout mice. Pain. 1998; 78: 115-121.
75. Murphy PG, Ramer MS, Borthwick L, Gauldie J, Richardson PM, Bisby MA. Endogenous interleukin-6 contributes to hypersensitivity to cutaneous stimuli and changes in neuropeptides associated with chronic nerve constriction in mice. Eur J Neurosci. 1999; 11: 2243-2253.
76. Hakkoum D, Stoppini L, Muller D. Interleukin-6 promotes sprouting and functional recovery in lesioned organotypic hippocampal slice cultures. J Neurochem. 2007; 100: 747-757.
77. Tancredi V, D'Antuono M, Cafè C, Giovedì S, Buè MC, D'Arcangelo G, et al. The inhibitory effects of interleukin-6 on synaptic plasticity in the rat hippocampus are associated with an inhibition of mitogen-activated protein kinase ERK. J Neurochem. 2000; 75: 634-643.
78. Deverman BE, Patterson PH. Cytokines and CNS development. Cell. 2009; 64: 61-78.
79. Altman J, Das GD. Autoradiographic and histological evidence of postnatal hippocampal neurogenesis in rats. J Comp Neurol. 1965; 124: 319-335.
80. Ekdahl CT, Claasen JH, Bonde S, Kokaia Z, Lindvall O. Inflammation is detrimental for neurogenesis in adult brain. Proc Natl Acad Sci U S A. 2003; 100: 13632-13637.
81. Whitney NP, Eidem TM, Peng H, Huang Y, Zheng JC. Inflammation mediates varying effects in neurogenesis: relevance to the pathogenesis of brain injury and neurodegenerative disorders. J Neurochem. 2009; 108: 1343-1359.
82. Vallieres L, Campbell IL, Gage FH, Sawchenko PE. Reduced hippocam-pal neurogenesis in adult transgenic mice with chronic astrocytic production of interleukin-6. J Neurosci. 2002; 22: 486-492.
83. Monje ML, Toda H, Palmer TD. Inflammatory blockade restores adult hippocampal neurogenesis. Science. 2003; 302: 1760-1765.
84. Nakanishi M, Niidome T, Matsuda S, Akaike A, Kihara T, Sugimoto H. Microglia-derived interleukin-6 and leukaemia inhibitory factor promote astrocytic differentiation of neural stem/progenitor cells. Eur J Neurosci. 2007; 25: 649-658.
85. Valerio A, Ferrario M, Dreano M, Garotta G, Spano P, Pizzi M. Soluble interleukin-6 (IL-6) receptor/IL-6 fusion protein enhances in vitro differentiation of purified rat oligodendroglial lineage cells. Mol Cell Neu-rosci. 2002; 21: 602-615.
86. Zhang PL, Izrael M, Ainbinder E, Ben-Simchon L, Chebath J, Revel M. Increased myelinating capacity of embryonic stem cell derived oli-godendrocyte precursors after treatment by interleukin-6/soluble inter-leukin-6 receptor fusion protein. Mol Cell Neurosci 2006; 31: 387-398.
87. Islam O, Gong X, Rose-John S, Heese K. Interleukin-6 and neural stem cells: more than gliogenesis. Mol Biol Cell. 2009; 20: 188-199.
88. Oh J, McCloskey MA, Blong CC, Bendickson L, Nilsen-Hamilton M, Sakaguchi DS. Astrocyte-derived interleukin-6 promotes specific neu-ronal differentiation of neural progenitor cells from adult hippocampus. J Neurosci Res. 2010; 88: 2798-2809.
89. Benveniste EN, Whitaker JN, Gibbs DA, Sparacio SM, Butler JL. Human B cell growth factor enhances proliferation and glial fibrillary acidic protein gene expression in rat astrocytes. Int Immunol. 1989; 1: 219-228.
90. Selmaj KW, Farooq M, Norton WT, Raine CS, Brosnan CF. Proliferation of astrocytes in vitro in response to cytokines. A primary role for tumor necrosis factor. J Immunol. 1990; 144: 129-135.
91. Levison SW, Jiang FJ, Stoltzfus OK, Ducceschi MH. IL-6-type cytokines enhance epidermal growth factor-stimulated astrocyte proliferation. Glia. 2000; 32: 328-337.
92. Streit WJ, Hurley SD, McGraw TS, Semple-Rowland SL. Comparative evaluation of cytokine profiles and reactive gliosis supports a critical role for interleukin-6 in neuron-glia signaling during regeneration. J Neuro-sci Res 2000; 61: 10-20.
93. März P, Heese K, Dimitriades-Schmutz B, Rose-John S, Otten U. Role of interleukin-6 and soluble IL-6 receptor in region-specific induction of astrocytic differentiation and neurotrophin expression. Glia. 1999; 26: 191-200.
94. Benveniste EN, Tang LP, Law RM. Differential regulation of astrocyte TNF-alpha expression by the cytokines TGF-beta, IL-6 and IL-10. Int J Dev Neurosci. 1995; 13: 341-349.
95. Meares GP, Ma X, Qin H, Benveniste EN. Regulation of CCL20 expression in astrocytes by IL-6 and IL-17. Glia. 2012; 60: 771-781.
96. Bolin LM, Zhaung A, Strychkarska-Orczyk I, Nelson E, Huang I, Malit M, et al. Differential inflammatory activation of IL-6 (-/-) astrocytes. Cytokine 2005; 30: 47-55.
97. Campbell IL, Abraham CR, Masliah E, Kemper P, Inglis JD, Oldstone MBA, et al. Neurologic disease in transgenic mice by cerebral overex-pression of interleukin 6. Proc Natl Acad Sci USA. 1993; 90: 10061-10065.
98. Chiang C-S, Stalder A, Samimi A, Campbell IL. Reactive gliosis as a consequence of interleukin 6 expression in the brain: studies in trans-genic mice. Dev Neurosci. 1994; 16: 212-221.
99. Fattori E, Lazzaro D, Musiani P, Modesti A, Alonzi T, Ciliberto G. IL-6 expression in neurons of transgenic mice causes reactive astrocytosis and increase in ramified microglial cells but no neuronal damage. Eur J Neurosci. 1995; 7: 2441-2449.
100. Giralt M, Penkowa M, Hernández J, Molinero A, Carrasco J, Lago N, et al. Metallothionein-1+2 deficiency increases brain pathology in trans-genic mice with astrocyte-targeted expression of interleukin 6. Neurobiol Dis. 2002; 9: 319-338.
101. Klein MA, Möller JC, Jones LL, Bluethmann H, Kreutzberg GW, Raivich G. Impaired neuroglial activation in interleukin-6 deficient mice. Glia. 1997; 19: 227-233.
102. Penkowa M, Moos T, Carrasco J, Hadberg H, Molinero A, Bluethmann H, et al. Strongly compromised inflammatory response to brain injury in interleukin-6-deficient mice. Glia. 1999; 25: 343-357.
103. Sugiura S, Lahav R, Han J, Kou SY, Banner LR, de Pablo F, et al. Leukaemia inhibitory factor is required for normal inflammatory responses to injury in the peripheral and central nervous systems in vivo and is chemotactic for macrophages in vitro. Eur J Neurosci. 2000; 12: 457-466.
104. Galiano M, Liu ZQ, Kalla R, Bohatschek M, Koppius A, Gschwendtner A, et al. Interleukin-6 (IL6) and cellular response to facial nerve injury: effects on lymphocyte recruitment, early microglial activation and ax-onal outgrowth in IL6-deficient mice. Eur J Neurosci. 2001; 14: 327-341.
105. Cardenas H, Bolin LM. Compromised reactive microgliosis in MPTP-lesioned IL-6 KO mice. Brain Res. 2003; 985: 89-97.
106. Shrikant P, Weber E, Jilling T, Benveniste EN. Intercellular adhesion molecule-1 gene expression by glial cells. Differential mechanisms of inhibition by IL-10 and IL-6. J Immunol. 1995; 155: 1489-1501.
107. Oh JW, Van Wagoner NJ, Rose-John S, Benveniste EN. Role of IL-6 and the soluble IL-6 receptor in inhibition of VCAM-1 gene expression. J Immunol. 1998; 161: 4992-4999.
108. Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity. 1997; 6: 315-325.
109. Pizzi M, Sarnico I, Boroni F, Benarese M, Dreano M, Garotta G, et al. Prevention of neuron and oligodendrocyte degeneration by interleukin-6 (IL-6) and IL-6 receptor/IL-6 fusion protein in organotypic hippocampal slices. Mol Cell Neurosci. 2004; 25: 301-311.
110. Zhang PL, Levy AM, Ben-Simchon L, Haggiag S, Chebath J, Revel M. Induction of neuronal and myelin-related gene expression by IL-6-receptor/IL-6: a study on embryonic dorsal root ganglia cells and isolated Schwann cells. Exp Neurol. 2007; 208: 285-296.
111. Schöbitz B, Pezeshki G, Pohl T, Hemmann U, Heinrich PC, Holsboer F, et al. Soluble interleukin-6 (IL-6) receptor augments central effects of IL-6 in vivo. FASEB J. 1995; 9: 659-664.
112. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med. 2002; 8: 75-79.
113. Faldt J, Wernstedt I, Fitzgerald SM, Wallenius K, Bergstrom G, Jansson JO. Reduced exercise endurance in interleukin-6-deficient mice. Endocrinology. 2004; 145: 2680-2686.
114. Wernstedt I, Edgley A, Berndtsson A, Faldt J, Bergstrom G, Wallenius V, et al. Reduced stress- and cold-induced increase in energy expenditure in interleukin-6-deficient mice. Am J Physiol Regul Integr Comp Physiol. 2006; 291: R551-R557.
115. Ruderman NB, Keller C, Richard AM, Saha AK, Luo Z, Xiang X, et al. Interleukin-6 regulation of AMP-activated protein kinase. Potential role in the systemic response to exercise and prevention of the metabolic syndrome. Diabetes 2006; 55 Suppl 2: S48-S54.
116. Navarra P, Pozzoli G, Brunetti L, Ragazzoni E, Besser M, Grossman AB. Interleukin-1 beta and interleukin-6 specifically increase the release of prostaglandin E2 from rat hypothalamic explants in vitro. Neuroendo-crinology. 1992; 56: 61-68.
117. Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin En-docrinol Metab. 1993; 77: 1690-1694.
118. Klir JJ, Roth J, Szelényi Z, McClellan JL, Kluger MJ. Role of hypothalamic interleukin-6 and tumor necrosis factor-alpha in LPS fever in rat. Am J Physiol Cell Physiol. 1993; 265: R512-R517.
119. Chai Z, Gatti S, Toniatti C, Poli V, Bartfai T. Interleukin (IL)-6 gene expression in the central nervous system is necessary for fever response to lipopolysaccharide or IL-1 beta: a study on IL-6-deficient mice. J Exp Med. 1996; 183: 311-316.
120. Herrmann O, Tarabin V, Suzuki S, Attigah N, Coserea I, Schneider A, et al. Regulation of body temperature and neuroprotection by endogenous interleukin-6 in cerebral ischemia. J Cereb Blood Flow Metab. 2003; 23: 406-415.
121. Morrow JD, Opp MR. Sleep-wake behavior and responses of interleu-kin-6-deficient mice to sleep deprivation. Brain Behav Immun. 2005; 19: 28-39.
122. Armario A, Hernández J, Bluethmann H, Hidalgo J. IL-6 deficiency leads to increased emotionality in mice: evidence in transgenic mice carrying a null mutation for IL-6. J Neuroimmunol. 1998; 92: 160-169.
123. Butterweck V, Prinz S, Schwaninger M. The role of interleukin-6 in stress-induced hyperthermia and emotional behaviour in mice. Behav Brain Res. 2003; 144: 49-56.
124. Bluthé RM, Michaud B, Poli V, Dantzer R. Role of IL-6 in cyto-kine-induced sickness behavior: a study with IL-6 deficient mice. Physiol Behav. 2000; 70: 367-373.
125. Heyser CJ, Masliah E, Samimi A, Campbell IL, Gold LH. Progressive decline in avoidance learning paralleled by inflammatory neurodegen-eration in transgenic mice expressing interleukin 6 in the brain. Proc Natl Acad Sci USA. 1997; 94: 1500-1505.
126. Baier PC, May U, Scheller J, Rose-John S, Schiffelholz T. Impaired hippocampus-dependent and -independent learning in IL-6 deficient mice. Behav Brain Res. 2009; 200: 192-196.
127. Balschun D, Wetzel W, Del Rey A, Pitossi F, Schneider H, Zuschratter W, et al. Interleukin-6: a cytokine to forget. FASEB J. 2004; 18: 1788-1790.
128. Hama T, Miyamoto M, Tsukui H, Nishio C, Hatanaka H. Interleukin-6 as a neurotrophic factor for promoting the survival of cultured basal fore-brain cholinergic neurons from postnatal rats. Neurosci Lett. 1989; 104: 340-344.
129. Hama T, Kushima Y, Miyamoto M, Kubota M, Takei N, Hatanaka H. Interleukin-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons from postnatal, two-week-old rats in cultures. Neuroscience. 1991; 40: 445-452.
130. Mendonça Torres PM, de Araujo EG. Interleukin-6 increases the survival of retinal ganglion cells in vitro. J Neuroimmunol. 2001; 117: 43-50.
131. Thier M, März P, Otten U, Weis J, Rose-John S. Interleukin-6 (IL-6) and its soluble receptor support survival of sensory neurons. J Neurosci Res 1999; 55: 411-422.
132. D'Arcangelo G, Tancredi V, Onofri F, D'Antuono M, Giovedì S, Benfenati F. Interleukin-6 inhibits neurotransmitter release and the spread of excitation in the rat cerebral cortex. Eur J Neurosci. 2000; 12: 1241-1252.
133. Murphy PG, Grondin J, Altares M, Richardson PM. Induction of inter-leukin-6 in axotomized sensory neurons. J Neurosci. 1995; 15: 5130-5138.
134. Hans VH, Kossmann T, Lenzlinger PM, Probstmeier R, Imhof HG, Trentz O, et al. Experimental axonal injury triggers interleukin-6 mRNA, protein synthesis and release into cerebrospinal fluid. J Cereb Blood Flow Metab. 1999; 19: 184-194.
135. Murphy PG, Borthwick LS, Johnston RS, Kuchel G, Richardson PM. Nature of the retrograde signal from injured nerves that induces inter-leukin-6 mRNA in neurons. J Neurosci. 1999; 19: 3791-3800.
136. Murphy PG, Borthwick LA, Altares M, Gauldie J, Kaplan D, Richardson PM. Reciprocal actions of interleukin-6 and brain-derived neurotrophic factor on rat and mouse primary sensory neurons. Eur J Neurosci. 2000; 12: 1891-1899.
137. Hirota H, Kiyama H, Kishimoto T, Taga T. Accelerated Nerve Regeneration in Mice by upregulated expression of interleukin (IL) 6 and IL-6 receptor after trauma. J Exp Med 1996; 183: 2627-2634.
138. Fisher J, Mizrahi T, Schori H, Yoles E, Levkovitch-Verbin H, Haggiag S, et al. Increased post-traumatic survival of neurons in IL-6-knockout mice on a background of EAE susceptibility. J Neuroimmunol. 2001; 119: 1-9.
139. Frei K, Leist T, Meager A, Gallo P, Leppert D, Zinkernagel R, et al. Production of B cell stimulatory factor-2 and interferon gamma in the central nervous system during viral meningitis and encephalitis. J Exp Med. 1988; 168: 449-453.
140. Grau GE, Frei K, Piguet PF, Fontana A, Heremans H, Billiau A, et al. Interleukin 6 production in experimental cerebral malaria: modulation by anticytokine antibodies and possible role in hypergammaglobuline-mia. J Exp Med. 1990; 172: 1505-1508.
141. Hirohata S, Miyamoto T. Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum. 1990; 33: 644-649.
142. Pagliusi SR, Schachner M, Seeburg PH, Shivers BD. The Adhesion Molecule on Glia (AMOG) Is Widely Expressed by Astrocytes in Developing and Adult Mouse Brain. Eur J Neurosci. 1990; 2: 471-480.
143. Laurenzi MA, Sidén A, Persson MA, Norkrans G, Hagberg L, Chiodi F. Cerebrospinal fluid interleukin-6 activity in HIV infection and inflammatory and noninflammatory diseases of the nervous system. Clin Immunol Immunopathol. 1990; 57: 233-241.
144. Kossmann T, Hans VH, Imhof HG, Stocker R, Grob P, Trentz O, et al. Intrathecal and serum interleukin-6 and the acute-phase response in patients with severe traumatic brain injuries. Shock. 1995; 4: 311-317.
145. Dalla Libera AL, Regner A, de Paoli J, Centenaro L, Martins TT, Simon D. IL-6 polymorphism associated with fatal outcome in patients with severe traumatic brain injury. Brain Injury. 2011; 25: 365-369.
146. Taupin V, Toulmond S, Serrano A, Benavides J, Zavala F. Increase in IL-6, IL-1 and TNF levels in rat brain following traumatic lesion. Influence of pre- and post-traumatic treatment with Ro5 4864, a peripheral-type (p site) benzodiazepine ligand. J Neuroimmunol. 1993; 42: 177-185.
147. Penkowa M, Giralt M, Carrasco J, Hadberg H, Hidalgo J. Impaired inflammatory response and increased oxidative stress and neurodegen-eration after brain injury in interleukin-6-deficient mice. Glia. 2000; 32: 271-285.
148. Swartz KR, Liu F, Sewell D, Schochet T, Campbell I, Sandor M, et al. Interleukin-6 promotes post-traumatic healing in the central nervous system. Brain Res. 2001; 896: 86-95.
149. Jones SA. Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol 2005; 175: 3463-3468.
150. Penkowa M, Giralt M, Lago N, Camats J, Carrasco J, Hernández J, et al. Astrocyte-targeted expression of IL-6 protects the CNS against a focal brain injury. Exp Neurol. 2003; 181: 130-148.
151. Poulsen CB, Penkowa M, Borup R, Nielsen FC, Caceres M, Quintana A, et al. Brain response to traumatic brain injury in wild-type and interleu-kin-6 knockout mice: a microarray analysis. J Neurochem. 2005; 92: 417-432.
152. Quintana A, Molinero A, Borup R, Nielsen FC, Campbell IL, Penkowa M, et al. Effect of astrocyte-targeted production of IL-6 on traumatic brain injury and its impact on the cortical transcriptome. Dev Neurobiol. 2008; 68: 195-208.
153. Beamer NB, Coull BM, Clark WM, Hazel JS, Silberger JR. Interleukin-6 and interleukin-1 receptor antagonist in acute stroke. Ann Neurol. 1995; 37: 800-805.
154. Tarkowski E, Rosengren L, Blomstrand C, Wikkelsö C, Jensen C, Ekholm S, et al. Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke. 1995; 26: 1393-1398.
155. Acalovschi D, Wiest T, Hartmann M, Farahmi M, Mansmann U, Auffarth GU, et al. Multiple levels of regulation of the interleukin-6 system in stroke. Stroke. 2003; 34: 1864-1869.
156. Smith CJ, Emsley HC, Gavin CM, Georgiou RF, Vail A, Barberan EM, et al. Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol. 2004; 4: 2.
157. Tso AR, Merino JG, Warach S. Interleukin-6 174G/C polymorphism and ischemic stroke: a systematic review. Stroke. 2007; 38: 3070-3075.
158. Loddick SA, Turnbull AV, Rothwell NJ. Cerebral interleukin-6 is neu-roprotective during permanent focal cerebral ischemia in the rat. J Cereb Blood Flow Metab. 1998; 18: 176-179.
159. Suzuki S, Tanaka K, Nogawa S, Nagata E, Ito D, Dembo T, et al. Temporal profile and cellular localization of interleukin-6 protein after focal cerebral ischemia in rats. J Cereb Blood Flow Metab. 1999; 19: 1256-1262.
160. Orzyłowska O, Oderfeld-Nowak B, Zaremba M, Januszewski S, Mossa-kowski M. Prolonged and concomitant induction of astroglial immuno-reactivity of interleukin-1beta and interleukin-6 in the rat hippocampus after transient global ischemia. Neurosci Lett. 1999; 263: 72-76.
161. Suzuki S, Tanaka K, Suzuki N. Ambivalent aspects of interleukin-6 in cerebral ischemia: inflammatory versus neurotrophic aspects. J Cereb Blood Flow Metab. 2009; 29: 464-479.
162. Minami M, Kuraishi Y, Satoh M. Effects of kainic acid on messenger RNA levels of IL-1 beta, IL-6, TNF alpha and LIF in the rat brain. Bio-chem Biophys Res Commun. 1991; 176: 593-598.
163. Suzuki S, Tanaka K, Nogawa S, Dembo T, Kosakai A, Fukuuchi Y. Expression of interleukin-6 is suppressed by inhibition of voltage-sensitive Na+/Ca2+ channels after cerebral ischemia. Neuroreport. 2000; 11: 2565-2569.
164. Yamashita T, Sawamoto K, Suzuki S, Suzuki N, Adachi K, Kawase T, et al. Blockade of interleukin-6 signaling aggravates ischemic cerebral damage in mice: possible involvement of Stat3 activation in the protection of neurons. J Neurochem. 2005; 94: 459-468.
165. Gertz K, Kronenberg G, Kälin RE, Baldinger T, Werner C, Balkaya M, et al. Essential role of interleukin-6 in post-stroke angiogenesis. Brain. 2012; in press.
166. Jung JE, Kim GS, Chan PH. Neuroprotection by interleukin-6 is mediated by signal transducer and activator of transcription 3 and antioxida-tive signaling in ischemic stroke. Stroke. 2011; 42: 3574-3579.
167. Peltola J, Palmio J, Korhonen L, Suhonen J, Miettinen A, Hurme M, et al. Interleukin-6 and interleukin-1 receptor antagonist in cerebrospinal fluid from patients with recent tonic-clonic seizures. Epilepsy Res. 2000; 41: 205-211.
168. Penkowa M, Molinero A, Carrasco J, Hidalgo J. Interleukin-6 deficiency reduces the brain inflammatory response and increases oxidative stress and neurodegeneration after kainic acid-induced seizures. Neuroscience. 2001; 102: 805-818.
169. De Sarro G, Russo E, Ferreri G, Giuseppe B, Flocco MA, Di Paola ED, et al. Seizure susceptibility to various convulsant stimuli of knockout in-terleukin-6 mice. Pharmacol Biochem Behav. 2004; 77: 761-766.
170. De Luca G, Di Giorgio RM, Macaione S, Calpona PR, Costantino S, Di Paola ED, et al. Susceptibility to audiogenic seizure and neurotransmit-ter amino acid levels in different brain areas of IL-6-deficient mice. Pharmacol Biochem Behav 2004; 78: 75-81.
171. Kalueff AV, Lehtimaki KA, Ylinen A, Honkaniemi J, Peltola J. Intranasal administration of human IL-6 increases the severity of chemically induced seizures in rats. Neurosci Lett. 2004; 365: 106-110.
172. Samland H, Huitron-Resendiz S, Masliah E, Criado J, Henriksen SJ, Campbell IL. Profound increase in sensitivity to glutamatergic- but not cholinergic agonist-induced seizures in transgenic mice with astrocyte production of IL-6. J Neurosci Res. 2003; 73: 176-187.
173. Conroy SM, Nguyen V, Quina LA, Blakely-Gonzales P, Ur C, Netzeband JG, et al. Interleukin-6 produces neuronal loss in developing cerebellar granule neuron cultures. J Neuroimmunol. 2004; 155: 43-54.
174. Qiu Z, Gruol DL. Interleukin-6, beta-amyloid peptide and NMDA interactions in rat cortical neurons. J Neuroimmunol. 2003; 139: 51-57.
175. Bauer J, Strauss S, Schreiter-Gasser U, Ganter U, Schlegel P, Witt I, et al. Interleukin-6 and alpha-2 macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett. 1991; 285: 111-114.
176. Strauss S, Bauer J, Ganter U, Jonas U, Berger M, Volk B. Detection of interleukin-6 and alpha 2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer's disease patients. Lab Invest. 1992; 66: 223-230.
177. Wood JA, Wood PL, Ryan R, Graff-Radford NR, Pilapil C, Robitaille Y, et al. Cytokine indices in Alzheimer's temporal cortex: no changes in mature IL-1 beta or IL-1RA but increases in the associated acute phase proteins IL-6, alpha 2-macroglobulin and C-reactive protein. Brain Res. 1993; 629: 245-252.
178. Hüll M, Strauss S, Berger M, Volk B, Bauer J. The participation of inter-leukin-6, a stress-inducible cytokine, in the pathogenesis of Alzheimer's disease. Behav Brain Res. 1996; 78: 37-41.
179. Hampel H, Haslinger A, Scheloske M, Padberg F, Fischer P, Unger J, et al. Pattern of interleukin-6 receptor complex immunoreactivity between cortical regions of rapid autopsy normal and Alzheimer's disease brain. Eur Arch Psychiatry Clin Neurosci. 2005; 255: 269-278.
180. Altstiel LD, Sperber K. Cytokines in Alzheimer's disease. Prog Neuro-psychopharmacol Biol Psychiatry. 1991; 15: 481-495.
181. Ringheim GE, Szczepanik AM, Petko W, Burgher KL, Zhu SZ, Chao CC. Enhancement of beta-amyloid precursor protein transcription and expression by the soluble IL-6 receptor/IL-6 complex. Mol Brain Res. 1998; 55: 35-44.
182. Chong Y. Effect of a carboxy-terminal fragment of the Alzheimer's amyloid precursor protein on expression of proinflammatory cytokines in rat glial cells. Life Sci. 1997; 61: 2323-2333.
183. Chakrabarty P, Jansen-West K, Beccard A, Ceballos-Diaz C, Levites Y, Verbeeck C, et al. Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J. 2010; 24: 548-559.
184. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med. 2006; 12: 1005-1015.
185. Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron. 2006; 49: 489-502.
186. Bolmont T, Haiss F, Eicke D, Radde R, Mathis CA, Klunk WE, et al. Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J Neurosci. 2008; 28: 4283-4292.
187. Funato H, Yoshimura M, Yamazaki T, Saido TC, Ito Y, Yokofujita J, et al. Astrocytes containing amyloid beta-protein (Abeta)-positive granules are associated with Abeta40-positive diffuse plaques in the aged human brain. Am J Pathol. 1998; 152: 983-992.
188. DeWitt DA, Perry G, Cohen M, Doller C, Silver J. Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer's disease. Exp Neurol. 1998; 149: 329-340.
189. Papassotiropoulos A, Bagli M, Jessen F, Bayer TA, Maier W, Rao ML, et al. A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease. Ann Neurol. 1999; 45: 666-668.
190. Capurso C, Solfrizzi V, D'Introno A, Colacicco AM, Capurso SA, Capurso A, et al. Interleukin 6-174 G/C promoter gene polymorphism and sporadic Alzheimer's disease: geographic allele and genotype variations in Europe. Exp Gerontol. 2004; 39: 1567-1573.
191. Han XM, Wang CH, Sima X, Liu SY. Interleukin-6 -174G/C polymorphism and the risk of Alzheimer's disease in Caucasians: a meta-analysis. Neurosci Lett 2011; 504: 4-8.
192. He MX, Yang WL, Zhang MM, Lian YJ, Hua HY, Zeng JS, et al. Association between interleukin-6 gene promoter -572C/G polymorphism and the risk of sporadic Alzheimer's disease. Neurol Sci. 2010; 31: 165-168.
193. Frei K, Fredrikson S, Fontana A, Link H. Interleukin-6 is elevated in plasma in multiple sclerosis. J Neuroimmunol. 1991; 31: 147-153.
194. Padberg F, Feneberg W, Schmidt S, Schwarz MJ, Körschenhausen D, Greenberg BD, et al. CSF and serum levels of soluble interleukin-6 receptors (sIL-6R and sgp130), but not of interleukin-6 are altered in multiple sclerosis. J Neuroimmunol. 1999; 99: 218-223.
195. Vladić A, Horvat G, Vukadin S, Sucić Z, Simaga S. Cerebrospinal fluid and serum protein levels of tumour necrosis factor-alpha (TNF-alpha) interleukin-6 (IL-6) and soluble interleukin-6 receptor (sIL-6R gp80) in multiple sclerosis patients. Cytokine. 2002; 20: 86-89.
196. Malmeström C, Andersson BA, Haghighi S, Lycke J. IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: implications for their possible immunopathogenic roles. J Neuroimmunol. 2006; 175: 176-182.
197. Maimone D, Guazzi GC, Annunziata P. IL-6 detection in multiple sclerosis brain. J Neurol Sci. 1997; 146: 59-65.
198. Fedetz M, Matesanz F, Pascual M, Martín J, Fernández O, Guerrero M, et al. The -174/-597 promoter polymorphisms in the interleukin-6 gene are not associated with susceptibility to multiple sclerosis. J Neurol Sci. 2001; 190: 69-72.
199. Schmidt S, Papassotiropoulos A, Sotgiu S, Kölsch H, Arru G, Fois ML, et al. Investigation of a genetic variation of a variable number tandem repeat polymorphism of interleukin-6 gene in patients with multiple sclerosis. J Neurol Sci. 2003; 250: 607-611.
200. Baxter AG. The origin and application of experimental autoimmune encephalomyelitis. Nat Rev Immunol. 2007; 7: 904-912.
201. Gijbels K, Van Damme J, Proost P, Put W, Carton H, Billiau A. Interleu-kin 6 production in the central nervous system during experimental autoimmune encephalomyelitis. Eur J Immunol. 1990; 20: 233-235.
202. Gijbels K, Brocke S, Abrams JS, Steinman L. Administration of neutralizing antibodies to interleukin-6 (IL-6) reduces experimental autoimmune encephalomyelitis and is associated with elevated levels of IL-6 bioactivity in central nervous system and circulation. Mol Med. 1995; 1: 795-805.
203. Serada S, Fujimoto M, Mihara M, Koike N, Ohsugi Y, Nomura S, et al. IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2008; 105: 9041-9046.
204. Okuda Y, Sakoda S, Bernard CC, Fujimura H, Saeki Y, Kishimoto T, et al. IL-6-deficient mice are resistant to the induction of experimental autoimmune encephalomyelitis provoked by myelin oligodendrocyte gly-coprotein. Int Immunol. 1998; 10: 703-708.
205. Mendel I, Katz A, Kozak N, Ben-Nun A, Revel M. Interleukin-6 functions in autoimmune encephalomyelitis: a study in gene-targeted mice. Eur J Immunol. 1998; 28: 1727-1737.
206. Eugster H-P, Frei K, Kopf M, Lassmann H, Fontana A. IL-6 deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. Eur J Immunol. 1998; 28: 2178-2187.
207. Samoilova EB, Horton JL, Hilliard B, Liu TS, Chen Y. IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells. J Immunol. 1998; 161: 6480-6486.
208. Linker RA, Lühder F, Kallen KJ, Lee DH, Engelhardt B, Rose-John S, et al. IL-6 transsignalling modulates the early effector phase of EAE and targets the blood-brain barrier. J Neuroimmunol. 2008; 205: 64-72.
209. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441: 235-238.
210. Murphy AC, Lalor SJ, Lynch MA, Mills KH. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav Immun. 2010; 24: 641-651.
211. Ogura H, Murakami M, Okuyama Y, Tsuruoka M, Kitabayashi C, Kanamoto M, et al. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity. 2008; 29: 628-636.
212. Quintana A, Müller M, Frausto RF, Ramos R, Getts DR, Sanz E, et al. Site-specific production of IL-6 in the central nervous system retargets and enhances the inflammatory response in experimental autoimmune encephalomyelitis. J Immunol. 2009; 183: 2079-2088.
213. Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, et al. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 1994; 180: 147-150.
214. Nagatsu T, Sawada M. Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. J Neural Transm Suppl 2007; 72: 113-120.
215. Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T. Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci Lett 1996; 211: 13-16.
216. Müller T, Blum-Degen D, Przuntek H, Kuhn W. Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease. Acta Neurol Scand. 1998; 98: 142-144.
217. Bolin LM, Strycharska-Orczyk I, Murray R, Langston JW, Di Monte D. Increased vulnerability of dopaminergic neurons in MPTP-lesioned in-terleukin-6 deficient mice. J Neurochem. 2002; 83: 167-175.
218. Akaneya Y, Takahashi M, Hatanaka H. Interleukin-1 beta enhances survival and interleukin-6 protects against MPP+ neurotoxicity in cultures of fetal rat dopaminergic neurons. Exp Neurol. 1995; 136: 44-52.
219. Björkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med. 2008; 205: 1869-1877.
220. Bensadoun JC, de Almeida LP, Dréano M, Aebischer P, Déglon N. Neu-roprotective effect of interleukin-6 and IL6/IL6R chimera in the quinolinic acid rat model of Huntington's syndrome. Eur J Neurosci. 2001; 14: 1753-1761.
221. Maes M, Scharpé S, Meltzer HY, Bosmans E, Suy E, Calabrese J, et al. Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatry Res. 1993; 49: 11-27.
222. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010; 67: 446-457.
223. Baker DG, Ekhator NN, Kasckow JW, Hill KK, Zoumakis E, Dashevsky BA, et al. Plasma and cerebrospinal fluid interleukin-6 concentrations in posttraumatic stress disorder. Neuroimmunomodulation. 2001; 9: 209-217.
224. Maes M, Lin AH, Delmeire L, Van Gastel A, Kenis G, De Jongh R, et al. Elevated serum interleukin-6 (IL-6) and IL-6 receptor concentrations in posttraumatic stress disorder following accidental man-made traumatic events. Biol Psychiatry. 1999; 45: 833-839.
225. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry. 2008; 63: 801-808.
226. Patterson PH. Immune involvement in schizophrenia and autism: etiology, pathology and animal models. Behav Brain Res 2009; 204: 313-321.
227. Smith SE, Li J, Garbett K, Mirnics K, Patterson PH. Maternal immune activation alters fetal brain development through interleukin-6. J Neu-rosci. 2007; 27: 10695-10702.
228. Wei H, Zou H, Sheikh AM, Malik M, Dobkin C, Brown WT, et al. IL-6 is increased in the cerebellum of autistic brain and alters neural cell adhesion, migration and synaptic formation. J Neuroinflammation. 2011; 8: 52.
229. Wei H, Chadman KK, McCloskey DP, Sheikh AM, Malik M, Brown WT, et al. Brain IL-6 elevation causes neuronal circuitry imbalances and mediates autism-like behaviors. Biochim Biophys Acta. 2012; 1822: 831-842.
230. März P, Otten U, Rose-John S. Neural activities of IL-6-type cytokines often depend on soluble cytokine receptors. Eur J Neurosci. 1999; 11: 2995-3004.
231. Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yama-moto N, et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity. 2001; 14: 705-714.
232. Nowell MA, Richards PJ, Horiuchi S, Yamamoto N, Rose-John S, Topley N, et al. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J Immunol. 2003; 171: 3202-3209.
233. Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. Faseb J. 2001; 15: 43-58.
234. Lemmers A, Gustot T, Durnez A, Evrard S, Moreno C, Quertinmont E, et al. An inhibitor of interleukin-6 trans-signalling, sgp130, contributes to impaired acute phase response in human chronic liver disease. Clin Exp Immunol. 2009; 156: 518-527.
235. Ding C, Jones G. Technology evaluation: MRA, Chugai. Curr Opin Mol Ther. 2003; 5: 64-69.
236. Ito H. Anti-interleukin-6 therapy for Crohn's disease. Curr Pharm Des. 2003; 9: 295-305.
237. Ding C, Cicuttini F, Li J, Jones G. Targeting IL-6 in the treatment of inflammatory and autoimmune diseases. Expert Opin Investig Drugs. 2009; 18: 1457-1466.
238. Tanaka T, Narazaki M, Kishimoto T. Therapeutic targeting of the inter-leukin-6 receptor. Annu Rev Pharmacol Toxicol. 2012; 52: 199-219.
239. Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med. 2000; 6: 583-588.
240. Nowell MA, Williams AS, Carty SA, Scheller J, Hayes AJ, Jones GW, et al. Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. J Immunol. 2009; 182: 613-622.
241. Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest. 2011; 121: 3375-3383.
242. Tenhumberg S, Waetzig GH, Chalaris A, Rabe B, Seegert D, Scheller J, et al. Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130. J Biol Chem. 2008; 283: 27200-27207.